4d Molecular Therapeutics, Inc.
A maker of genetic medicines, 4D Molecular Therapeutics engineers custom viral delivery vehicles to treat diseases of the eye, lung, and heart. Founded in 2013 by a UC Berkeley professor and a biotech entrepreneur who met at a university innovation hub, the company got its start in a garage incubator. Its name reflects the four dimensions of optimization its scientists pursue when designing the adeno-associated virus vectors that carry therapeutic genes into the body.
Sold 540.0K
Granted 75.9K · Sold 411.6K
Granted 2.2K · Sold 779
Granted 9.3K
Granted 55.7K · Sold 62.1K
Granted 24.0K · Sold 24.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kolchinsky Peter +3 co-filers10% owner · 1 transaction | — | 4.56Mas of Dec 2024 | — | — | — |
| Halvorsen Ole Andreas +7 co-filers10% owner · 1 transaction | -11.3% | 4.25Mas of Jan 2024 | — | — | 540.0K |
| Kirn DavidSee Remarks, Director · 17 transactions | -55.6% | 825.8K | 75.9K | — | 411.6K |
| Biotechnology Value Fund II LP +9 co-filersSee Explanation of Responses · 3 transactions | -57.8% | 663.0Kas of Nov 2024 | — | — | — |
| Gupta AshooVP, Finance and Controller · 8 transactions | — | 47.1K | 2.2K | — | 779 |
| Theuer CharlesDirector · 1 transaction | +28.8% | 41.7K | 9.3K | — | — |
| Bizily ScottChief Legal Officer · 56 transactions | +235.8% | 18.4K | 55.7K | — | 62.1K |
| Kim Robert YoungChief Medical Officer · 7 transactions | — | 1.6Kas of Feb 2024 | 24.0K | — | 24.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.04M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.